ILD-TYPE p53 acts as a transcriptional factor and can transactivate and control expression of other genes including GADD45' and 1ndm2.'-~ After DNA damage, elevated levels of p53 occur, which are required to cause GI arrest of the cell to allow for DNA repair or apopt~sis.~-~ This blockade of DNA synthesis prevents accumulation of mutations that would promote evolution into cancer cells. The mechanism by which elevated levels of p53 blocks cellular growth is now becoming clear. Expression of a new gene, known as wild-type p53-activated fragment 1 (WAF1); also known as p21, Cipl, SDI1, or Pic-l) is directly regulated by p53 and can itself suppress the growth of human cells in culture by blocking the activity of cyclin-dependent kinases A mouse homologue of WAFl has also been Cells deficient in p53 have no active WAFl (p21) after treatment with DNA-damaging radiation or chemotherap~.'~.'' The WAFl gene is localized to chromosome 6~21.2, and several tumors have been noted to have losses of this chromosomal region."" Because WAFl is a negative regulator of the cell cycle, it can act as a tumor suppressor gene, and mutational inactivation of the gene may contribute to the development of several malignancies in cells containing wild-type. p53 gene. In this study, potential alterations of the WAFl gene were examined in a variety of human primary tumors (many of which contained no detectable p53 mutation) and in cell lines by single-strand conformation polymorphism (SSCP) using polymerase chain reaction (PCR) and sequencing analysis of appropriate samples.
ILD-TYPE p53 acts as a transcriptional factor and can transactivate and control expression of other genes including GADD45' and 1ndm2.'-~ After DNA damage, elevated levels of p53 occur, which are required to cause GI arrest of the cell to allow for DNA repair or apopt~sis.~-~ This blockade of DNA synthesis prevents accumulation of mutations that would promote evolution into cancer cells. The mechanism by which elevated levels of p53 blocks cellular growth is now becoming clear. Expression of a new gene, known as wild-type p53-activated fragment 1 (WAF1); also known as p21, Cipl, SDI1, or Pic-l) is directly regulated by p53 and can itself suppress the growth of human cells in culture by blocking the activity of cyclin-dependent kinases A mouse homologue of WAFl has also been Cells deficient in p53 have no active WAFl (p21) after treatment with DNA-damaging radiation or chemotherap~.'~.'' The WAFl gene is localized to chromosome 6~21.2, and several tumors have been noted to have losses of this chromosomal region."" Because WAFl is a negative regulator of the cell cycle, it can act as a tumor suppressor gene, and mutational inactivation of the gene may contribute to the development of several malignancies in cells containing wild-type. p53 gene. In this study, potential alterations of the WAFl gene were examined in a variety of human primary tumors (many of which contained no detectable p53 mutation) and in cell lines by single-strand conformation polymorphism (SSCP) using polymerase chain reaction (PCR) and sequencing analysis of appropriate samples. PCR-SSCP analysis to screen for WAF1 mutations. The PCR-SSCP analysis was performed using a modification of a previously reported method." This technique is based on the phenomenon that a change of base sequence (eg, mutation) has an effect on the folding conformation of single-stranded DNA and, thus, affects the rate of the vulvar carcinoma samples had HPV sequences ( Table  I ) . No abnormal WAF1 band shifts were noted in any of the samples, but 3 variant patterns were observed in both exon 2a and 3. Thus, we obtained matched tumor and adjacent normal DNAs from 36 lung cancer patients. Paired samples of tumor and normal DNAs were amplified by PCR and run on gel for SSCP analysis of WAF1 gene. Three patterns of band shifts were identically detected in exon 2a in both tumor and normal DNAs from the same patients (Fig   2) . and these polymorphisms occurred in both the homozygous and heterozygous state. Sequence analysis o f the amplified products from normal DNAs producing each SSCP pattern showed that the sequence variation was present at codon 3 1 : one allele (allele A) is AGC (serine) and the other (allele B) is AGA (arginine) (Fig 3) . These results indicate the presence of a polymorphism. Among the 36 matched samples. 3 I were homozygous for allelle A, 2 were homozygous for allele B, and 3 of 36 were heterozygous (8%). The percentage of heterozygosity including a l l primary samplcs was 15% (Table I ) .
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Similarly, analysis of exon no. 3 showed three patterns of band shift recognized by PCR-SSCP of DNAs of the malignancies. Further studies also showed that paired samples of normal and tumor DNAs from the lung cancer patients had a similar pattern of band shifts. suggesting two different alleles. Sequence analysis of each of the representative normal DNA samples showed that this sequence variation is because of a single base-pair substitution of C to T at the 590th base. This result suggested that this sequence variation is also a polymorphism, a s observed in exon no. 2a. Among the 36 matched samples, 32 were homozygous for one allele. I was homozygous for the second allele. and 3 were heterozygous (8%). The percentage of heterozygosity including all primary samples was 15% ( Table I) . The SSCP analysis of exon no. 2h showed only one pattern of band shift, and no abnormal pattern was observed among a l l the samples.
We studied loss of heterozygosity (LOH) using matched samples from 36 lung cancer patients. Of the six informative cases, we could not detect LOH for either exons no. 2a or 3 (data not shown).
DISCUSSION
Recent studies have shown that cyclins and their related cdks play an important role in the control of the cell cycle.'"3'' The pS3-activated WAF1 (Cipl, SDI 1. Pic-I , p2 I ) inhibits the cdks, which can result in a block in the cell cyc~e~ll'.ll.14.1"17 The wild-type p53 can directly and potently transactivate the WAF1 gene.'"." Therefore, the WAFl gene product may be an important component linking p53 to the cell-cycle controls that can result in growth suppression. Therefore, mutations of the WAF1 gene might release the cell from these negative growth controls, contributing to transformation of cells that have a normal p53. Alterations of this DNA-damage inducible p53 pathway may contribute to resistance of tumors to chemotherapy. Examination of 3 15 primary samples from 14 different types of human malignancies detected no WAF1 mutations. Importantly. of 290 preselected samples, 90% had no detectable p53 mutation. Because of the known ability of E6 protein of HPV to inactivate pS3, cervical and vulvar cancers were preselected for samples that were HPV-negati~e.'~.?' Also, none of the renal tumors had mdm-2 amplification that is capable of binding and inactivating ~5 3 . " We also analyzed DNAs from 36 cell lines that originated from a variety of malignancies, and no mutations of WAF1 were found. Although SSCP has been shown to be a very sensitive method for detecting point mutations, mutations were possibly missed by this screening method. However, we have previously detected a relatively high incidence of p53 mutations (>80%) in anaplastic thyroid cancers using exactly the same methods."' In addition, we were able to detect DNA polymorphisms within two different regions of the WAF1 gene using this technique. Thus. most sequence variations should have been detected.
Mutational inactivation of a tumor suppressor gene often occurs by a point mutation of one allele and loss of the remaining normal allele. Several tumors. such as renal cell carcinoma.'" colorectal cancer.'" glioma." and ovarian cancei' have been reported to have losses of the chromosomal region containing WAF1 gene. Among these malignancies, ovarian cancer has a high frequency (62%) of LOH for the chromosome 6p." In this study, we examined S 1 renal cell, colon, and ovarian cancers and detected no WAF1 mutations. even though only a total of 16% of the renal and colon cancers had p53 alterations. (The frequency of p53 mutations in the ovarian cancer samples is unknown.) Also, no LOH in the WAF1 gene was detected in matched samples of 36 lung cancer patients; however. the number of informative samples was small.
The absence of WAF1 alterations in a large series of human malignancies suggests that WAF1 mutations may not play an important role in either the onset or the progression of these malignancies. The p53 may activate additional critical tumor suppressor pathways, or alternate elements of the cell-cycle machinery may be derranged, such a s abnormal expression of either the cyclins or cdks.3x,'','' Additionally. defective induction of WAF1 protein expression after DNA damage may result in a defective p53 pathways in some tumors.I7
A recent study has found that another cdk inhibitor known as p16 is frequently mutated in human tumor cell lines.u,'5 It specifically inhibits cdk4, which becomes active when associated with D cyclins in the G, phase of the cell cycle."' Why might mutations of p16. but not WAF, frequently be associated with cellular transformation'? Unlike p16. which is a specific inhibitor of cdk4. WAF1 is a universal inhibitor of all the cdks; perhaps. mutation and inactivation of WAF1 is catastrophic, resulting in death of the cell. Therefore, if they exist, WAF1 mutations in human neoplasia will be rare. Furthermore, WAFl mutations may be present in a subtype of cancer that we have not yet examined. such as those with known deletions of human chromosome 6p and wild-type p53 or those with no p53 mutation but which also have no G , arrest after their exposure to a DNA damaging agent.
Conceivably. loss of one allele of 6p may contribute to defective WAFl induction by p53. Perhaps, WAF1 protein levels are critical for their negative regulation of cell-cycle progression."." For personal use only. on October 3, 2017. by guest www.bloodjournal.org From
